Moderna reaffirms 2023 COVID vaccine sales outlook; shares tumble
Maddie Meyer/Getty Images News

Moderna (NASDAQ:MRNA) reaffirmed its forecast of $6 billion to $8 billion for COVID vaccine sales for the year, after rival Pfizer (PFE) slashed its outlook due to lower than expected sales for its COVID products.
Shares of Moderna tumbled nearly 8% in early trading. 
The company added that it belives it is still too early in the U.S. vaccination season to accurately predict vaccination rates for the full year, and expects "improved visibility" about the expected U.S. market size after seeing trends through October. 

More on Moderna

Investing In Moderna: A Speculative Buy For Long-Term Gains
Moderna: Now That The COVID Party Is Over, What's Next?
Moderna: Covid Curse
More than 7M Americans have received updated COVID shots
Moderna says Noubar Afeyan sells 15K shares in the company